Product name | Recombinant Human VEGF-A/VEGF165 Protein |
---|---|
Catalog No. | RP01150 |
Description | Recombinant Human VEGF-A/VEGF165 Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Ala27-Arg191) of human VEGF165 (Accession #NP_001165097.1) fused with a 6×His tag at the N-terminus. |
Bio-Activity |
1.Measured by its binding ability in a functional ELISA. Immobilized Recombinant Human VEGF165 at 1 μg/mL (100 μL/well) can bind Recombinant Human VEGFR2 with a linear range of 8-20 ng/mL. 2.Measured by its binding ability in a functional ELISA. Immobilized Human VEGF165 at 2 μg/mL (100 μL/well) can bind Human KDR with a linear range of 0.2-11.6 ng/mL. |
Purity | > 97% by SDS-PAGE. |
Endotoxin | < 0.1 EU/μg of the protein by LAL method. |
Formulation | Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4.Contact us for customized product form or formulation. |
Species | Human |
Storage | Store the lyophilized protein at -20°C to -80 °C for long term. After reconstitution, the protein solution is stable at -20 °C for 3 months, at 2-8 °C for up to 1 week. |
---|---|
Reconstitution | Centrifuge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid votex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles. |
Submit your question about RP01150 below and we will get back to you within one business day.
Alternatively, call us at 888.754.5670.
Publishing research using RP01150? Please let us know so that we can cite the reference in this datasheet.
* For research use only. Not for therapeutic or diagnostic purposes.